Table 3.
Differences in means (95% CI; p) or odds ratio (95% CI; p) of the outcomes used to compare treatment and dosage groups.
| Quantitative outcomes: difference in means (95% CI); p | Binary outcomes: OR (95% CI); p | ||||||
|---|---|---|---|---|---|---|---|
| Fetlock circumference | Total protein | Log10 (PGE2) | Log10 (CTX-II) | Total nucleated cell counts | Joint effusion | Synovial fluid effusion | |
| Autologous BM-MSCs vs. placebo | 0.2 (-0.7 to 1.1); 0.66 | 0.5 (0.1 to 0.8); 0.006 ∗ | -0.07 (-0.3 to 0.1); 0.50 | -0.1 (-0.2 to 0.03); 0.008 ∗ | 6.7 (1.5 to 29.8); 0.01 ∗ | NC | NC |
| Allogenic BM-MSCs vs. placebo | 0.1 (-0.8 to 1); 0.77 | 0.2 (0.05 to 0.4); 0.01 ∗ | -0.15 (-0.4 to 0.08); 0.20 | -0.1 (-0.2 to 0.01); 0.06 | 8.0 (1.9 to 33.7); 0.005 ∗ | NC | NC |
| Allogenic UCB-MSCs vs. placebo | 0.2 (0.1 to 0.3); 0.006 ∗ | 0.5 (0.1 to 0.8); 0.005 ∗ | -0.08 (-0.2 to 0.04); 0.20 | -0.2 (-0.2 to -0.1); <0.0001 ∗ | 12 (1.7 to 83.5); 0.01 ∗ | NC | NC |
| Autologous vs. allogenic BM-MSCs | 0.07 (-0.1 to 0.2); 0.38 | 0.2 (-0.002 to 0.4); 0.052 | 0.08 (-0.05 to 0.2); 0.24 | -0.03 (-0.1 to 0.1); 0.67 | 0.8 (0.3 to 2.3); 0.74 | 0.6 (0.3 to 1.1); 0.12 | 0.5 (0.3 to 0.8); 0.004 ∗ |
| Autologous BM vs. allogenic UCB-MSCs | 0.001 (-1 to 1); 0.10 | -0.01 (-0.3 to 0.3); 0.94 | 0.001 (-0.2 to 0.2); 0.99 | 0.02 (-0.1 to 0.1); 0.65 | 0.6 (0.1 to 2.5); 0.44 | 0.9 (0.3 to 1.9); 0.75 | 1.1 (0.6 to 2); 0.68 |
| Allogenic BM vs. allogenic UCB-MSCs | -0.07 (-1 to 0.9); 0.88 | -0.2 (-0.5 to 0.03); 0.08 | -0.07 (-0.3 to 0.1); 0.50 | 0.04 (-0.04 to 0.1); 0.30 | 0.7 (0.2 to 2.6); 0.55 | 1.5 (1 to 2.4); 0.049 ∗ | 2.2 (1.3 to 3.9); 0.004 ∗ |
| 10 vs. 20 million cells | 0.5 (-0.9 to 2); 0.48 | 0.2 (-0.1 to 0.5); 0.26 | 0.1 (-0.1 to 0.3); 0.2 | -0.27 (-0.4 to 0.1); 0.003 ∗ | 4.2 (1.5 to 11.5); 0.005 ∗ | 7.0 (1.7 to 28.3); 0.006 ∗ | 9.4 (1.9 to 46); 0.006 ∗ |
OR: odds ratio; CI: confidence interval; NC: not comparable with the model used; ∗ p < 0.05.